Companies · Biotechnology

V ClinBio LLC

NEWARK · Biotechnology

Diligence memoA one-page analyst read on V ClinBio LLC — recommendation, valuation, rhythm, risks.
$13.7M
Total raised · real
2
Rounds
2.5×
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Thu Oct 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

V ClinBio LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.67× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

V ClinBio LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.0 yr record
Peak capital year was 2017 with $13.7M across 2 filings.
Market position
ahead of 61% of Biotechnology peers
Capital scale is ahead of 61% of Biotechnology peers; modeled value is above 78% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $13.7M across 2 filings.
  • Largest single filing was $9.8M on 2017-10-05.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

V ClinBio LLC is one of 4291 Biotechnology companies tracked from NEWARK. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2013
Year incorporated
2017-10-05
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2017-07-14 Raised $3.9M (real) Modeled valuation $173M (est)$3.9M$173MSeed2017Series A · 2017-10-05 Raised $9.8M (real) Modeled valuation $352M (est)$9.8M$352MSeries A2017+$9.8MCumulative $14M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.9M · 2017
Series A$9.8M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$352.5M
Base estimate est.
$10.6M
Conservative case
$1.9B
Upside case
$44.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $173.2M · 2017-07-142017Series A · modeled $352.5M · 2017-10-052017
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
8.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
Capital velocity
9.0 yr
On record since
2017
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$13.7M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.8× above median
This company$9.8M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 5.5× above median
This company$352.5M
Sector median$64.2M

Raised more than 61% of sector peers (real $). Modeled value above 78% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #33 of 157.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)V ClinBio LLC (this company) Raised $13.7M · modeled $352.5M (est)V ClinBio LLC
CompanyStageRaised · realValue · estvs peer med.
Cynvec LLCSeries A$17.4M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
V ClinBio LLC this companySeries A$13.7M$352.5M1.67×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.9M2017-07-14$19.5M$173.2M90%
Series A$9.8M2017-10-05$44.3M$352.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.9M2017-07-14
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Series A$9.8M2017-10-05
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 7 investors on this round.
Intelligence
2017 ~Q4
Modeled next raise · ~3mo cadence
$24.4M
Modeled next size est.range $15.8M$39.0M
2.5×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Raghu Rao3 other2017-07
Subramaniam Apparsundaram1 other2017-07
Registry & provenance

V ClinBio LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1712942
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Vibe Bioscience CorpBiotechnologySeries A$13.7M$476.8Msame sector · same stage
Peloton Therapeutics, Inc.BiotechnologySeries A$13.7M$423.0Msame sector · same stage
Aleta Biotherapeutics, Inc.BiotechnologySeries A$13.7M$306.4Msame sector · same stage
NeuroSigma, Inc.BiotechnologySeries A$13.8M$421.3Msame sector · same stage
Revitope Oncology, Inc.BiotechnologySeries A$13.4M$296.4Msame sector · same stage
Adjuvance Technologies Inc.BiotechnologySeries A$13.4M$385.3Msame sector · same stage
BioTrove, Inc.BiotechnologySeries A$13.3M$481.3Msame sector · same stage
BrainXell, Inc.BiotechnologySeries A$13.2M$274.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Qc Clb I, LlcBiotechnologySeries A$414.8M88%
Halodine LLCBiotechnologySeed$18.9M84%
VQ Biomedical, Inc.BiotechnologySeed$7.6M84%
VelosBio Inc.BiotechnologySeries D+$5.6B83%
Merus N.V.BiotechnologySeries C$614.4M83%
Vail Scientific, L.L.C.BiotechnologySeries A$27.0M83%
Cleave Biosciences, Inc.BiotechnologySeries B$475.1M83%
Bioincept LlcBiotechnologySeries A$99.3M83%
Frequently asked
How much funding has V ClinBio LLC raised?
V ClinBio LLC has raised approximately $13.7M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is V ClinBio LLC's estimated valuation?
Provath's modeled valuation for V ClinBio LLC is approximately $352.5M (modeled range $10.6M–$1.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is V ClinBio LLC at?
V ClinBio LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Oct 05.
What does V ClinBio LLC do and where is it based?
V ClinBio LLC operates in the Biotechnology sector, based in NEWARK.
Explore related

See where V ClinBio LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at V ClinBio LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.